BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25286347)

  • 1. In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.
    Marsouvanidis PJ; Melis M; de Blois E; Breeman WA; Krenning EP; Maina T; Nock BA; de Jong M
    Cancer Biother Radiopharm; 2014 Nov; 29(9):359-67. PubMed ID: 25286347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
    Maina T; Kaloudi A; Valverde IE; Mindt TL; Nock BA
    Nucl Med Biol; 2017 Sep; 52():57-62. PubMed ID: 28636973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
    Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
    Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
    Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee Sy; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
    Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
    Nock BA; Maina T; Krenning EP; de Jong M
    J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
    Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
    Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
    Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
    J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
    Schroeder RP; de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Breeman WA; Krenning EP; de Jong M
    Int J Cancer; 2010 Jun; 126(12):2826-34. PubMed ID: 19876914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
    Lymperis E; Kaloudi A; Sallegger W; Bakker IL; Krenning EP; de Jong M; Maina T; Nock BA
    Bioconjug Chem; 2018 May; 29(5):1774-1784. PubMed ID: 29664606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
    Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
    Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
    J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.
    Hoffman TJ; Gali H; Smith CJ; Sieckman GL; Hayes DL; Owen NK; Volkert WA
    J Nucl Med; 2003 May; 44(5):823-31. PubMed ID: 12732685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.
    García Garayoa E; Schweinsberg C; Maes V; Rüegg D; Blanc A; Bläuenstein P; Tourwé DA; Beck-Sickinger AG; Schubiger PA
    Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):42-50. PubMed ID: 17372572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon.
    Kaloudi A; Nock BA; Lymperis E; Krenning EP; de Jong M; Maina T
    Cancer Biother Radiopharm; 2016 Feb; 31(1):20-8. PubMed ID: 26844849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.